drugset / Trial / NCT04134325
Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
Phase 0
Active not recruiting
10 enrolled
UNC Lineberger Comprehensive Cancer Center
American Society of Clinical Oncology · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
LCCC1852-ATL is a prospective 2-arm study designed to determine if chimeric antigen receptor T (CAR-T) cells result in immunomodulation which can be subsequently exploited by programmed cell death protein 1 (PD-1) antibodies to achieve clinical responses in subjects with relapsed/refractory (r/r) classical Hodgkin Lymphoma (cHL).
Timeline
- Start
- 2019-09-01
- Primary completion
- 2025-04-01
- Completion
- 2037-07-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 240 mg | — |
| Subject | Nivolumab | Monoclonal antibody | 480 mg | — |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | — |
| Subject | Pembrolizumab | Monoclonal antibody | 400 mg | — |